Back to team

Timothy Herpin, PhD

Chief Business Officer

,

Tim Herpin has over 20 years of business development experience in biotech and pharmaceutical companies. Until recently, he was Chief Business Officer at Santa Ana Bio, a precision immunology company developing antibodies and ADCs for autoimmune and inflammatory diseases. During the pandemic, he served as Vice President, Janssen Business Development, Infectious Diseases and Vaccines, leading the strategy and planning of all business development activities in support of the therapeutic area.  Before J&J, he was the Chief Business Officer at Caribou Biosciences, a privately held gene editing company based in the Bay Area. Prior to that, Tim was Vice-President, Head of Transactions at AstraZeneca and led a group of business development professionals involved in all aspects of transaction negotiation and execution. Tim joined AstraZeneca in 2011 as Vice-President, Strategic Partnering and Business Development, covering all business development activities for the Neuroscience disease area and subsequently for the Oncology disease area. Prior to AstraZeneca, Tim spent eight years in the business development organization at Bristol-Myers Squibb, covering both search and evaluation as well as transactions in multiple disease areas. Over his business development career, Tim has led deals of all sizes from research collaborations to multi-billion M&A, and deals of all shapes from licensing transactions to Series B financing. Tim started his career as a medicinal chemist at Bristol-Myers Squibb, Aventis, and Pharmacopeia.

Tim grew up in Paris and is a graduate of École Polytechnique in France. He holds a PhD in organic chemistry from University College London and an MBA in Finance from NYU Stern.